Related Experiment Video
Updated: Jan 28, 2026

Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Abdullah Al Emran1, Aniruddha Chatterjee2, Euan J Rodger3
1Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; These authors contributed equally.
Abstract:
Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by inhibiting endogenous interferon responses needed for recognition of cancer cells. By contrast, global hypomethylation results in the expression of programmed death ligand 1 (PD-L1) and inhibitory cytokines, accompanied by epithelial-mesenchymal changes that can contribute to immunosuppression. The drivers of these contrasting methylation states are not well understood. DNA methylation also plays a key role in cytotoxic T cell 'exhaustion' associated with tumor progression. We present an updated exploratory analysis of how DNA methylation may define patient subgroups and can be targeted to develop tailored treatment combinations to help improve patient outcomes.
Insights
DNA methylation patterns influence cancer immunotherapy. Hypermethylation can hinder immune responses, while hypomethylation may promote tumor evasion, highlighting methylation as a therapeutic target.
Area of Science:
- Epigenetics
- Cancer Biology
- Immunology
Background:
- DNA methylation at CpG sites is a stable epigenetic modification in cancer.
- Hypermethylation can limit immune checkpoint blockade immunotherapy by suppressing interferon responses.
- Global hypomethylation is linked to PD-L1 expression, immunosuppression, and epithelial-mesenchymal transition.
Purpose of the Study:
- To explore how DNA methylation defines cancer patient subgroups.
- To investigate DNA methylation as a target for tailored cancer treatment combinations.
Main Methods:
- Exploratory analysis of DNA methylation data.
- Correlation of methylation states with immune responses and tumor progression.
Main Results:
- Contrasting roles of DNA hypermethylation and hypomethylation in cancer immunity.
- DNA methylation's involvement in cytotoxic T cell exhaustion.
- Identification of potential patient subgroups based on methylation profiles.
Conclusions:
- DNA methylation patterns significantly impact the tumor microenvironment and response to immunotherapy.
- Targeting DNA methylation offers a strategy for developing novel, personalized cancer therapies.
Related Concept Videos
Tumor Immunotherapy
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
Resistance
DNA-only Transposons
The donor site from where the transposon is excised is either degraded or...
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. ...

